In today’s complex healthcare landscape, controlling costs and improving member health outcomes is more important than ever. MedImpact’s clinical team is continually conducting research to find ways to help our clients do just that.

At AMCP 2026, the leading annual conference for managed care professionals, we presented our latest research on: 

• Evaluating characteristics of medication nonadherence
• Predicting the financial impact of newly approved therapies

And we won the Platinum Ribbon!

Read more below.

POSTER 1

Evaluating characteristics of nonadherence 

Addressing medication nonadherence is critical to improving health outcomes.

While refill reminder programs are often implemented to address this challenge, they can also be used to collect information that can help payers proactively identify members at risk of nonadherence so timely interventions can be made.

Leveraging this data, our team conducted a study to evaluate common characteristics among Part D members who were nonadherent in three medication classes: diabetes, hypertension, and statins. And their findings underscore the value of this outreach for payers and PBMs.

PLATINUM RIBBON WINNER
Characteristics associated with nonadherence from data collected as part of an automated refill reminder program 
Authors: James Chamberlain, PharmD, MS, Shellie Keast, PharmD, PhD, Jennifer Hendricks, PharmD, APh, BCACP, CDCES, FCPhA

POSTER 2

Predicting the financial impact of new therapies 

According to the CDC, approximately 1.6 million cases of new gonococcal infections are diagnosed in the US each year. Of those, only 35% are diagnosed–with 70% of identified cases being treated. While the current standard of care for uncomplicated urogenital gonorrhea is a single dose of intramuscular ceftriaxone, two additional treatments were approved by the FDA at the end of last year: gepotidacin and zoliflodacin. 

To help commercial plans better understand the future financial impact of these new therapies, MedImpact conducted an investigation using a budget impact model (BIM) and found potential increases in PMPM that payers may need to prepare for.

Budget impact model of new oral treatments for uncomplicated urogenital gonorrhea
Authors: Shellie Keast, PharmD, PhD, James Chamberlain, PharmD, MS, Wenyi Qiu, MS, Jennifer Hendricks, PharmD, APh, BCACP, CDCES, FCPhA